International Journal of Cancer Management

Published by: Kowsar

Modified Intermediate-Dose Cytarabine Combined with Daunorubicin Induction and Re-Induction Protocol Use in Patients with Acute Myeloid Leukemia

Mozaffar Aznab 1 , * and Omid Beiki 1 , 2
Authors Information
1 Kermanshah University of Medical Sciences, Kermanshah, Iran
2 Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
Article information
  • International Journal of Cancer Management: April 2017, 10 (4); e7000
  • Published Online: March 26, 2017
  • Article Type: Research Article
  • Received: May 17, 2016
  • Revised: July 2, 2016
  • Accepted: March 14, 2017
  • DOI: 10.5812/ijcm.7000

To Cite: Aznab M, Beiki O. Modified Intermediate-Dose Cytarabine Combined with Daunorubicin Induction and Re-Induction Protocol Use in Patients with Acute Myeloid Leukemia, Int J Cancer Manag. 2017 ; 10(4):e7000. doi: 10.5812/ijcm.7000.

Abstract
Copyright © 2017, International Journal of Cancer Management. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Introduction
2. Methods
3. Results
4. Discussion
Acknowledgements
Footnotes
References
  • 1. SEER Stat Fact Sheets: Acute Myeloid Leukemia. 2012;
  • 2. Szer J. The prevalent predicament of relapsed acute myeloid leukemia. Hematology Am Soc Hematol Educ Program. 2012; 2012: 43-8[DOI][PubMed]
  • 3. Cancer Facts and Figures 2014. 2014;
  • 4. Archimbaud E, Thomas X, Leblond V, Michallet M, Fenaux P, Cordonnier C, et al. Timed sequential chemotherapy for previously treated patients with acute myeloid leukemia: long-term follow-up of the etoposide, mitoxantrone, and cytarabine-86 trial. J Clin Oncol. 1995; 13(1): 11-8[DOI][PubMed]
  • 5. Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med. 1994; 331(14): 896-903[DOI][PubMed]
  • 6. Champlin R, Gajewski J, Nimer S, Vollset S, Landaw E, Winston D, et al. Postremission chemotherapy for adults with acute myelogenous leukemia: improved survival with high-dose cytarabine and daunorubicin consolidation treatment. J Clin Oncol. 1990; 8(7): 1199-206[DOI][PubMed]
  • 7. Thomas X, Raffoux E, Renneville A, Pautas C, de Botton S, de Revel T, et al. Outcome of treatment after first relapse in younger adults with acute myeloid leukemia initially treated by the ALFA-9802 trial. Leuk Res. 2012; 36(9): 1112-8[DOI][PubMed]
  • 8. Naina HV, Patnaik MM, Harris S. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med. 2009; 361(26): 2578[DOI][PubMed]
  • 9. Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010; 115(3): 453-74[DOI][PubMed]
  • 10. Buchner T, Berdel WE, Schoch C, Haferlach T, Serve HL, Kienast J, et al. Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia. J Clin Oncol. 2006; 24(16): 2480-9[DOI][PubMed]
  • 11. Bradstock KF, Matthews JP, Lowenthal RM, Baxter H, Catalano J, Brighton T, et al. A randomized trial of high-versus conventional-dose cytarabine in consolidation chemotherapy for adult de novo acute myeloid leukemia in first remission after induction therapy containing high-dose cytarabine. Blood. 2005; 105(2): 481-8[DOI][PubMed]
  • 12. Lowenberg B, Pabst T, Vellenga E, van Putten W, Schouten HC, Graux C, et al. Cytarabine dose for acute myeloid leukemia. N Engl J Med. 2011; 364(11): 1027-36[DOI][PubMed]
  • 13. Castaigne S, Chevret S, Archimbaud E, Fenaux P, Bordessoule D, Tilly H, et al. Randomized comparison of double induction and timed-sequential induction to a "3 + 7" induction in adults with AML: long-term analysis of the Acute Leukemia French Association (ALFA) 9000 study. Blood. 2004; 104(8): 2467-74[DOI][PubMed]
  • 14. Breems DA, Boogaerts MA, Dekker AW, Van Putten WL, Sonneveld P, Huijgens PC, et al. Autologous bone marrow transplantation as consolidation therapy in the treatment of adult patients under 60 years with acute myeloid leukaemia in first complete remission: a prospective randomized Dutch-Belgian Haemato-Oncology Co-operative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) trial. Br J Haematol. 2005; 128(1): 59-65[DOI][PubMed]
  • 15. Wolff SN, Herzig RH, Fay JW, Phillips GL, Lazarus HM, Flexner JM, et al. High-dose cytarabine and daunorubicin as consolidation therapy for acute myeloid leukemia in first remission: long-term follow-up and results. J Clin Oncol. 1989; 7(9): 1260-7[DOI][PubMed]
  • 16. De Witte T, Suciu S, Selleslag D, Labar B, Roozendaal K, Zittoun R, et al. Salvage treatment for primary resistant acute myelogenous leukemia consisting of intermediate-dose cytosine arabinoside and interspaced continuous infusions of idarubicin: a phase-II study (no. 06901) of the EORTC Leukemia Cooperative Group. Ann Hematol. 1996; 72(3): 119-24[PubMed]
  • 17. Lowenberg B. Sense and nonsense of high-dose cytarabine for acute myeloid leukemia. Blood. 2013; 121(1): 26-8[DOI][PubMed]
  • 18. Fukushima T, Urasaki Y, Yamaguchi M, Ueda M, Morinaga K, Haba T, et al. A randomized comparison of modified intermediate-dose Ara-C versus high-dose ara-c in post-remission therapy for acute myeloid leukemia. Anticancer Res. 2012; 32(2): 643-7[PubMed]
  • 19. Bishop JF, Matthews JP, Young GA, Szer J, Gillett A, Joshua D, et al. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood. 1996; 87(5): 1710-7[PubMed]
  • 20. Weick JK, Kopecky KJ, Appelbaum FR, Head DR, Kingsbury LL, Balcerzak SP, et al. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. Blood. 1996; 88(8): 2841-51[PubMed]
  • 21. Lowenberg B, van Putten W, Theobald M, Gmur J, Verdonck L, Sonneveld P, et al. Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. N Engl J Med. 2003; 349(8): 743-52[DOI][PubMed]
  • 22. Pagano L, Pulsoni A, Vignetti M, Tosti ME, Falcucci P, Fazi P, et al. Secondary acute myeloid leukaemia: results of conventional treatments. Experience of GIMEMA trials. Ann Oncol. 2005; 16(2): 228-33[DOI][PubMed]
  • 23. Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med. 1999; 341(14): 1051-62[DOI][PubMed]
  • 24. Wiernik PH, Banks PL, Case DJ, Arlin ZA, Periman PO, Todd MB, et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood. 1992; 79(2): 313-9[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .
Readers' Comments